Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
MDSAP Certification Achievement: Alpha Tau Medical Ltd. has received MDSAP certification for its manufacturing facility in Jerusalem, enhancing its commitment to quality and regulatory compliance while facilitating the global expansion of its alpha-radiation cancer therapy, Alpha DaRT.
Alpha DaRT Technology Overview: The Alpha DaRT therapy is designed for targeted treatment of solid tumors through intratumoral delivery of radium-224, aiming to effectively destroy tumor cells while minimizing damage to surrounding healthy tissue.
Get Free Real-Time Notifications for Any Stock
Analyst Views on DRTSW
No data
About the author
Alpha Tau Achieves First Patient Treatment in U.S. Multi-Center Clinical Trial for Pancreatic Cancer
Pilot Study Initiation: Alpha Tau Medical has commenced a multi-center pilot study, IMPACT, to evaluate the safety and efficacy of Alpha DaRT combined with chemotherapy for patients with newly diagnosed unresectable pancreatic adenocarcinoma, a condition affecting up to 87% of patients at diagnosis.
Innovative Treatment Approach: The study aims to provide a localized treatment option using Alpha DaRT's targeted alpha radiation, potentially improving outcomes for patients with limited treatment options, while continuing their standard chemotherapy regimen.
Alpha Tau to Attend Five Investor Conferences in September
Company Announcement: Alpha Tau Medical Ltd. announced that CFO Raphi Levy will present at five investor conferences in September 2025, focusing on their innovative cancer therapy, Alpha DaRT.
Alpha DaRT Technology: The Alpha DaRT platform utilizes localized alpha particle radiotherapy to target solid tumors while minimizing damage to surrounding healthy tissue, with promising immuno-stimulatory effects.
Upcoming Conferences: Key events include the Citi 2025 Biopharma Summit, H.C. Wainwright Global Investment Conference, and others, where Mr. Levy will be available for one-on-one meetings with investors.
Forward-Looking Statements: The press release contains forward-looking statements regarding clinical trials and regulatory approvals, highlighting uncertainties and potential risks associated with the company's future performance.